– USA, CA – Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Steve Schoch to its Board of Directors as Chair of the Audit Committee.
Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in biopharmaceuticals, media, and technology, including building and scaling businesses and leading innovation.
“We are very pleased to have Mr. Schoch join our Board of Directors,” said Board chair, Dr. Garry Neil. “Steven brings both financial and strategic operational experience that will be of great benefit as Arena prepares for the next stage of growth.”
About Steve Schoch
Mr. Schoch currently serves as CFO at 23andMe, a position he has held since 2018. Before joining 23andMe, Mr. Schoch served as the CEO of Miramax Film NY, LLC from 2012 to 2017, while concurrently serving as CFO, a position he held beginning in 2010. From 2001 to 2010, Mr. Schoch held various senior financial positions at Amgen, Inc., including Corporate Controller and divisional Financial VP. He served as the EVP and CFO of eToys, Inc. from 1999 to 2001. Before eToys, Inc., Mr. Schoch held a variety of financial positions in the media industry, including at The Walt Disney Company and the Times Mirror Company.
Mr. Schoch holds a B.S. in Civil Engineering degree from Tufts University and an M.B.A. degree from the Tuck School of Business Administration, Dartmouth College.
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients.
In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it’s done.
We are developing a richly diversified portfolio of therapeutic candidates targeting gastroenterology, dermatology, and cardiology. Our pipeline includes four investigational medicines in eight indications and eleven ongoing or planned clinical trials. To fuel our growth, we are unlocking the value of our historical GPCR research with a sustainable discovery engine for broad portfolio expansion.
For more information : https://www.arenapharm.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
